Renal Cell Carcinoma: Understanding Kidney Cancer and How It Is Treated Today
Every year, more than 430,000 people worldwide receive a diagnosis of renal cell carcinoma — the most common form of kidney cancer in adults. Decades ago, a diagnosis of advanced RCC carried a grim prognosis, with few treatment options and median survival measured in months. Today, the landscape has been fundamentally transformed. A surge of targeted molecular therapies, improved surgical techniques, and a growing understanding of the genetic underpinnings of the disease have made RCC one of the most actively evolving areas in oncological urology.
Yet despite this progress, kidney cancer remains widely misunderstood by the general public. Many patients are diagnosed incidentally — not because of symptoms, but because an imaging scan done for an unrelated reason happens to reveal a suspicious kidney mass. Understanding what RCC is, how it develops, what modern treatment looks like, and what emerging therapies offer is increasingly important — both for patients facing a diagnosis and for anyone seeking to understand the current frontiers of cancer medicine.
What Is Renal Cell Carcinoma?
Renal cell carcinoma arises from the epithelial cells lining the small tubules of the kidney — the microscopic structures responsible for filtering blood and producing urine. It accounts for approximately 85–90% of all primary kidney cancers. The remaining cases include transitional cell carcinoma of the renal pelvis and rarer entities such as Wilms tumor in children.
RCC is not a single disease. It encompasses several distinct biological subtypes, each with characteristic genetic alterations, behavior, and prognosis.
Major Subtypes of Renal Cell Carcinoma
- Clear cell RCC (ccRCC): The most common subtype, comprising 70–80% of cases. Almost universally associated with loss-of-function mutations or hypermethylation of the VHL (von Hippel-Lindau) tumor suppressor gene, leading to abnormal activation of hypoxia-inducible factors and vascular growth pathways.
- Papillary RCC: The second most common subtype (10–15%), further divided into Type 1 (associated with MET gene mutations) and Type 2 (associated with FUMARATE HYDRATASE mutations in hereditary cases).
- Chromophobe RCC: Approximately 5% of cases; generally carries a more favorable prognosis than clear cell RCC.
- Collecting duct carcinoma and medullary carcinoma: Rare, aggressive subtypes with poor outcomes.
- Unclassified RCC: Tumors that do not fit neatly into established categories.
Risk Factors and Who Gets Kidney Cancer
Certain factors are known to increase the risk of developing RCC:
- Tobacco smoking — the single most important modifiable risk factor, increasing relative risk by approximately 1.5-fold
- Obesity — particularly associated with clear cell RCC; adipose tissue may influence hormonal and metabolic pathways that promote tumorigenesis
- Hypertension — an independent risk factor, likely mediated by chronic renal damage and cellular hypoxia
- Occupational exposures — trichloroethylene, asbestos, and certain petroleum products have been implicated
- Chronic renal failure and dialysis — patients with end-stage renal disease have markedly increased RCC incidence
- Hereditary syndromes — von Hippel-Lindau (VHL) disease, hereditary papillary RCC, and Birt-Hogg-Dubé syndrome account for approximately 3–5% of all cases
- Male sex and age — men are affected roughly twice as often as women; peak incidence is in the sixth and seventh decades
Diagnosis: Often Found by Accident
The so-called “classic triad” of kidney cancer — flank pain, blood in the urine (hematuria), and a palpable abdominal mass — now presents in fewer than 10% of patients, typically indicating locally advanced disease. The majority of RCC diagnoses today are incidental, discovered during ultrasound or CT imaging performed for unrelated indications such as abdominal pain, hernia evaluation, or routine health screening.
This epidemiological shift toward incidental detection has meaningfully improved outcomes, since tumors found incidentally tend to be smaller, organ-confined, and more amenable to curative treatment.
Key Diagnostic Tools
- Ultrasound: Often the initial modality; can distinguish solid from cystic masses but cannot characterize malignant potential with precision
- CT with contrast (CT urography): The gold standard for staging and characterizing renal masses; evaluates tumor size, venous involvement, lymph node spread, and distant metastases
- MRI: Particularly useful when CT findings are equivocal or when contrast is contraindicated (e.g., renal impairment)
- Renal mass biopsy: Increasingly employed to differentiate between benign oncocytoma, angiomyolipoma, and malignant lesions before committing to surgery or active surveillance
The Bosniak classification system is used to categorize cystic kidney lesions by imaging characteristics, helping guide management decisions from surveillance to surgical resection.
Staging: How Far Has the Cancer Spread?
The TNM staging system (Tumor, Node, Metastasis) governs how kidney cancer is classified clinically and pathologically. Treatment decisions and prognosis are heavily influenced by stage at diagnosis.
| Stage | Description | 5-Year Survival (Approximate) |
| Stage I | Tumor ≤7 cm, confined to kidney | 81–96% |
| Stage II | Tumor >7 cm, confined to kidney | 74–83% |
| Stage III | Extends beyond kidney fat / venous involvement / single lymph node | 53–64% |
| Stage IV | Invades beyond Gerota’s fascia or distant metastases | 8–20% |
Approximately 30% of patients have metastatic disease at initial diagnosis. Of those initially treated with curative intent, up to 30% will relapse with distant metastases over time, most commonly in the lungs, bones, liver, and brain.
Surgical Treatment: The Foundation of Curative Management
For localized RCC — stages I through III without distant spread — surgery remains the primary curative approach. The key principle governing surgical decision-making is maximum oncological control balanced with maximum renal function preservation.
Radical Nephrectomy
Radical nephrectomy — removal of the entire kidney along with its surrounding fat and, in some cases, the ipsilateral adrenal gland and regional lymph nodes — was for decades the standard treatment for all RCC regardless of tumor size. It remains appropriate for large tumors, multifocal disease, and cases where partial removal is not technically feasible.
Partial Nephrectomy (Nephron-Sparing Surgery)
For tumors 4 cm or smaller — and selectively for tumors up to 7 cm — partial nephrectomy is now the preferred approach in patients with a normal contralateral kidney. Landmark evidence established that partial nephrectomy achieves equivalent oncological outcomes to radical nephrectomy for T1a tumors while preserving functional renal mass, reducing the long-term risk of chronic kidney disease, cardiovascular events, and dialysis dependence.
Both approaches are increasingly performed via minimally invasive routes — laparoscopic or robotic-assisted surgery — offering reduced blood loss, shorter hospital stays, and faster recovery compared to open surgery.
Ablative Technologies
For patients who are poor surgical candidates, percutaneous image-guided ablation using radiofrequency energy (RFA) or cryotherapy can be used to destroy small renal tumors. These approaches have acceptable local recurrence rates for tumors under 3 cm and are particularly valuable in elderly or medically frail patients.
Targeted Therapy: The Revolution in Advanced RCC
For decades, metastatic RCC was treated with cytokine immunotherapy — high-dose interleukin-2 (IL-2) or interferon-alpha. Response rates were modest (15–20%), toxicity was significant, and durable remissions were rare. Then came the molecular understanding of clear cell RCC, and with it an entirely new therapeutic era.
The VHL-HIF Pathway: The Master Switch
In clear cell RCC, loss of the VHL protein results in constitutive activation of hypoxia-inducible factors (HIF-1α and HIF-2α), which drive the expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and other pro-angiogenic molecules. Tumors effectively trick the body into feeding them with new blood vessels. This molecular insight unlocked a cascade of therapeutic targets.
VEGF-Targeting Agents
The first generation of targeted agents for metastatic RCC consisted of tyrosine kinase inhibitors (TKIs) that block VEGF receptor signaling:
- Sunitinib and sorafenib became the founding agents of this class, replacing interferon as the standard of care for first-line treatment of advanced clear cell RCC in 2006–2007
- Pazopanib and axitinib followed as second-generation TKIs with refined selectivity profiles
- These agents demonstrated significant improvements in progression-free survival and, in some analyses, overall survival compared to prior standards
mTOR Inhibitors
The mammalian target of rapamycin (mTOR) pathway intersects with the HIF signaling axis and regulates cell growth and metabolism. Temsirolimus and everolimus inhibit mTOR and showed activity particularly in poor-prognosis or VHL-independent disease.
The Immunotherapy Renaissance: Checkpoint Inhibitors
The most recent transformation in RCC treatment has come from immune checkpoint inhibitors — agents that release inhibitory signals on tumor-reactive T cells, allowing the immune system to recognize and attack cancer cells. Combinations such as nivolumab plus ipilimumab (dual PD-1/CTLA-4 blockade) and pembrolizumab plus axitinib have demonstrated superior outcomes to TKI monotherapy in favorable- and intermediate-risk metastatic RCC, and have become standard first-line regimens in major guidelines.
Active Surveillance: When Watchful Waiting Is Appropriate
Not every kidney mass requires immediate treatment. For small renal masses (under 2 cm), particularly in elderly patients or those with significant comorbidities, active surveillance — regular imaging monitoring without intervention — is a reasonable strategy. Growth rates of small incidentally detected RCC are often slow (under 3 mm/year), and progression to metastasis is uncommon in carefully selected patients. This approach spares patients from unnecessary surgical risk while maintaining the option to intervene if the lesion grows or changes in character.
Conclusion: A Disease Being Redefined
Renal cell carcinoma has been transformed — from a largely surgical disease with poor options at advanced stages to a condition now addressed through precision molecular therapy, sophisticated surgical technique, and immunological reactivation. The insights pioneered in foundational reviews such as Canda and Kirkali’s 2006 Urology Journal analysis of targeted therapy laid intellectual groundwork that the subsequent decade of clinical trials built upon, ultimately delivering the immunotherapy combinations that now anchor modern first-line treatment.
For anyone diagnosed with a kidney mass, the most important first step remains prompt evaluation by a urologist or uro-oncologist who can determine whether the lesion is suspicious, whether biopsy is appropriate, and what stage and subtype information should guide treatment planning. Early-stage RCC is highly curable with surgery. Even metastatic disease, once considered near-uniformly fatal, is now manageable for many patients over sustained periods.
To read the latest peer-reviewed research on renal cell carcinoma and urological oncology, visitUrology Journal.